Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Citi
AstraZeneca
Argus Health
Healthtrust
Harvard Business School
Daiichi Sankyo
Federal Trade Commission
Colorcon
Teva

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,442,049

« Back to Dashboard

Summary for Patent: 5,442,049
Title: Oligonucleotides for modulating the effects of cytomegalovirus infections
Abstract:Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides such as ISIS 2922 are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.
Inventor(s): Anderson; Kevin (Carlsbad, CA), Draper; Kenneth (Boulder, CO), Baker; Brenda (Encinitas, CA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:08/009,263
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 5,442,049

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,442,049

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany 69133405 ➤ Subscribe
Germany 69133511 ➤ Subscribe
Germany 69230223 ➤ Subscribe
Canada 2331334 ➤ Subscribe
Canada 2333087 ➤ Subscribe
Canada 2353090 ➤ Subscribe
Canada 2353108 ➤ Subscribe
Canada 2373225 ➤ Subscribe
Australia 8440391 ➤ Subscribe
Australia 661662 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
Johnson and Johnson
Accenture
Fuji
Federal Trade Commission
Chinese Patent Office
Argus Health
Cipla
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot